National Health Act 1953 - Amendment determinations under sections 85, 85a and 88 - pharmaceutical benefits (No. PB 88 of 2010) (Cth)

Case

COMMONWEALTH OF AUSTRALIA

Instrument number PB 88 of 2010

Amendment determinations under sections 85, 85A and 88 of the National Health Act 1953

I, DAVID LEARMONTH, Deputy Secretary, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under sections 85, 85A and 88 of the National Health Act 1953.

Dated   17 September 2010

DAVID LEARMONTH

Deputy Secretary

Department of Health and Ageing

Amendment determination — pharmaceutical benefits

1              Commencement

This instrument commences on 1 October 2010.

2              Amendment of PB 68 of 2010

Schedule 1 amends PB 68 of 2010.

Schedule 1            Amendments

  1. Part 1 of Schedule 1, item dealing with Amoxycillin with Clavulanic Acid in the form Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

insert in alphabetical order in the column headed “Brand”: Amoxycillin/Clavulanic Acid 500/125 generichealth

  1. Part 1 of Schedule 1, item dealing with Amoxycillin with Clavulanic Acid in the form Tablet containing 875 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

insert in alphabetical order in the column headed “Brand”: Amoxycillin/Clavulanic Acid 875/125 generichealth

  1. Part 1 of Schedule 1, after item dealing with Electrolyte Replacement, Solution

insert in the columns in the order indicated:

Eletriptan

Tablet 40 mg (as hydrobromide)

Oral

4

5

Relpax

Tablet 80 mg (as hydrobromide)

Oral

4

5

Relpax

  1. Part 1 of Schedule 1, item dealing with Lamotrigine in the form Tablet 50 mg

insert in alphabetical order in the column headed “Brand”: APO-Lamotrigine

  1. Part 1 of Schedule 1, item dealing with Lisinopril in the forms Tablet 5 mg, Tablet 10 mg and Tablet 20 mg

omit from the column headed “Brand”: Lisinobell

  1. Part 1 of Schedule 1, item dealing with Memantine in the form Tablet containing memantine hydrochloride 10 mg

insert in alphabetical order in the column headed “Brand”: APO-Memantine

  1. Part 1 of Schedule 1, item dealing with Metformin in the forms Tablet containing metformin hydrochloride 500 mg, Tablet containing
    metformin hydrochloride 850 mg and Tablet containing metformin hydrochloride 1 g

insert in alphabetical order in the column headed “Brand”: Glucohexal

  1. Part 1 of Schedule 1, item dealing with Metformin in the forms Tablet containing metformin hydrochloride 500 mg and Tablet containing metformin hydrochloride 850 mg

omit from the column headed “Brand”: Metforbell

  1. Part 1 of Schedule 1, item dealing with Omeprazole in the form Tablet 20 mg

insert in alphabetical order in the column headed “Brand”: Omeprazole generichealth

  1. Part 1 of Schedule 1, item dealing with Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate)

(a)     insert in alphabetical order in the column headed “Brand”: Pantofast 40

(b)     insert in alphabetical order in the column headed “Brand”: Pantoprazole generichealth

  1. Part 1 of Schedule 1, item dealing with Pantoprazole in the form Tablet (enteric coated) 20 mg (as sodium sesquihydrate)

(a)     insert in alphabetical order in the column headed “Brand”: Pantofast 20

(b)     insert in alphabetical order in the column headed “Brand”: Pantoprazole generichealth

  1. Part 1 of Schedule 1, item dealing with Ranitidine in the form Tablet 300 mg (as hydrochloride)

insert in alphabetical order in the column headed “Brand”: Ranitidine Sandoz

  1. Part 1 of Schedule 1, item dealing with Simvastatin in the forms Tablet 5 mg, Tablet 10 mg, Tablet 20 mg, Tablet 40 mg and Tablet 80 mg

omit from the column headed “Brand”: Simvabell

  1. Part 1 of Schedule 1, item dealing with Terbinafine in the form Tablet 250 mg (as hydrochloride)

(a)     omit from the column headed “Brand”: Terbinafine-DP

(b)     insert in alphabetical order in the column headed “Brand”: Terbinafine-DRLA

  1. Part 2 of Schedule 1, item dealing with Omeprazole in the form Tablet 20 mg

insert in alphabetical order in the column headed “Brand”: Omeprazole generichealth

  1. Part 2 of Schedule 1, item dealing with Pantoprazole in the form Tablet (enteric coated) 40 mg (as sodium sesquihydrate)

(a)     insert in alphabetical order in the column headed “Brand”: Pantofast 40

(b)     insert in alphabetical order in the column headed “Brand”: Pantoprazole generichealth

  1. Part 2 of Schedule 1, item dealing with Simvastatin in the forms Tablet 5 mg, Tablet 10 mg, Tablet 20 mg, Tablet 40 mg and Tablet 80 mg

omit from the column headed “Brand”: Simvabell

  1. Part 2 of Schedule 1, item dealing with Terbinafine in the form Tablet 250 mg (as hydrochloride)

(a)     omit from the column headed “Brand”: Terbinafine-DP

(b)     insert in alphabetical order in the column headed “Brand”: Terbinafine-DRLA

  1. Part 1 of Schedule 3, item dealing with Amoxycillin with Clavulanic Acid in the form Tablet containing 500 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

insert in alphabetical order in the column headed “Brand”: Amoxycillin/Clavulanic Acid 500/125 generichealth

  1. Part 1 of Schedule 3, item dealing with Amoxycillin with Clavulanic Acid in the form Tablet containing 875 mg amoxycillin (as trihydrate) with 125 mg clavulanic acid (as potassium clavulanate)

    insert in alphabetical order in the column headed “Brand”: Amoxycillin/Clavulanic Acid 875/125 generichealth

Note

All legislative instruments and compilations are registered on the Federal Register of Legislative Instruments kept under the Legislative Instruments Act 2003.

See

Actions
Download as PDF Download as Word Document
Cases Citing This Decision

0

Cases Cited

0

Statutory Material Cited

0